SSRIs and sleep in man

Sleep and Sleep Disorders: A Neuropsychopharmacological Approach

Volumn , Issue , 2006, Pages 269-273

  Wilson, Sue J ^a   Nutt, David J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920002963     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-27682-3_31     Document Type: Chapter

References (58)

1. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999; 60(Suppl 17):28-31.
2. Thase ME, Buysse DJ, Frank E et al. Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEC sleep profiles. Am J Psychiatry 1997; 154(4):502-9.
3. Feige B, Voderholzer U, Riemann D et al. Fluoxetine and sleep EEC: Effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 2002; 26(2):246-58.
4. Van Bemmel AL, van den Hoofdakker RH, Beersma DGM et al. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology 1993; 113:225-230.
5. Rush AJ, Armitage R, Gillin JC et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998; 44(1):3-14.
6. Borbely AA. A two process model of sleep regulation. Hum Neurobiol 1982; 1(3): 195-204.
7. Ehlers CL, Havstad JW, Kupfer DJ. Estimation of the time course of slow-wave sleep over the night in depressed patients: Effects of clomipramine and clinical response. Biol Psychiatry 1996; 39(3):171-81.
8. Veitch W, Wilson SJ, Argyropoulos S et al. Slow waves in sleep are altered by paroxetine and nefazodone in depressed patients. J Psychopharm 2001; 15(3 suppl):A18.
9. Monaca C, Boutrel B, Hen R et al. 5-HT lA/lB receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: Studies in 5-HT lA and 5-HT IB knockout mice. Neuropsychopharmacology 2003; 28(5):850-6.
10. Monti JM, Monti D. Role of dorsal raphe nucleus serotonin 5HTla receptor in the regulation of REM sleep. Life Sciences 2000; 66:1999-2012.
11. Wilson SJ, Bailey JE, Rich AS et al. Effects of 5HT1A agonists on sleep in normal volunteers: A comparison of eptapirone, Buspirone, and placebo. J Psychopharm 2003; 17(3 suppl):A73.
12. Hicks JA, Argyropoulos SV, Rich AS et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002; 180:528-35.
13. Vasar V, Appelberg B, Rimon R et al. The effect of fluoxetine on sleep: A longitudinal double blind polysomnographic study of healthy volunteers. International Clinical Psychopharmacology 1994; 9:203-206.
14. Wilson SJ, Bailey JE, Alford C et al. Effects of 5 weeks of administration of fluoxetine and dothiepin in normal volunteers on sleep, daytime sedation, psychomotor performance and mood. J Psychopharmacol 2002; 16(4):321-31.
15. Argyropoulos SV, Hicks JA, Nash Jr et al. Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Res 2003; 120(2): 179-90.
16. Wilson SJ, Bell C, Coupland NJ et al. Sleep changes during long-term treatment of depression with fluvoxamine - A home based study. Psychopharmacology 2000; 149:360-365.
17. Ridout F, Meadows R, Johnsen S et al. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 2003; 18(4):261-9.
18. Ohayon MM, Roth T. Prevalence of resdess legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002; 53(1):547-54.
19. Schenck CH, Mahowald MW, Kim SW et al. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep 1992; 15(3):226-35.
20. Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 1993; 54(11):432-4.
21. Pagel JF, Helfter P. Drug induced nightmares-An etiology based review. Hum Psychopharmacol 2003; 18(1):59-67.
22. Lepkiflcer E, Dannon PN, lancu I et al. Nightmares related to fluoxetine treatment. Clin Neuropharmacol 1995; 18:90-94.
23. Markowitz JC. Fluoxetine and dreaming. J Clin Psychiatry 1991; 52(10):432.
24. Koponen, H, Lepola U, Leiononen E et al. Citalopram in the treatment of obsessive-compulsive disorder: An open pilot study. Acta Psychiat Scand 1997; 96:343-346.
25. Kirschner NT. Medication and dreams: Changes in dream content after drug treatment. Dreaming 1999; 9:195-200.
26. Pace-Schott EF, Gersh T, Silvestri R et al. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 2001; 10(2):129-42.
27. Stein DJ, Davidson J, Seedat S et al. Paroxetine in the treatment of post-traumatic stress disorder: Pooled analysis of placebo-controlled studies. Expert Opin Pharmacodier 2003; 4(10):1829-38.
28. Nowell PD, Reynolds CF 3rd, Buysse DJ et al. Paroxetine in the treatment of primary insomnia: Preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry 1999; 60(2):89-95.
29. Goldenberg D, Mayskiy M, Mossey C et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39(11): 1852-9.
30. Vercoulen JH, Swanink CM, Zitman FG et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996; 347(9005):858-61.
31. Wilson SJ, Lillywhite AR, Potokar JP et al. Adult night terrors and paroxetine. Lancet 1997; 350(9072): 185.
32. Bengtson H, Broman J-E, Hetta J. The effect of paroxetine on sleepwalking in 8 adults. Sleep Research Online 1999; 2(S1): 131.
33. Kopelman PC, Elliott MW, Simonds A et al. Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. Int J Obes Relat Metab Disord 1992; 16(10):825-30.
34. Kraiczi H, Hedner J, Dahlof P et al. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999; 22(1):61-7.
35. Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest 1991; 100(2):416-21.
36. Manfredi RL, Kales A, Vgontzas AN et al. Buspirone: Sedative or stimulant effect? Am J Psychiatry 1991; 148(9): 1213-7.
37. Gillin JC, Sohn JW, Stahl SM et al. Ipsapirone, a 5-HTlA agonist, suppresses REM sleep equally in unmedicated depressed patients and normal controls. Neuropsychopharmacology 1996; 15(2): 109-15.
38. Ware JC, Rose FV, McBrayer RH. The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 1994; 17(6):544-50.
39. Gillin JC, Jernajczyk W, Valladares-Neto DC et al. Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers. Psychopharmacology (Berl) 1994; 116(4):433-6.
40. Seifritz E, Moore P, Trachsel L et al. The 5-HTlA agonist ipsapirone enhances EEC slow wave activity in human sleep and produces a power spectrum similar to 5-HT2 blockade. Neurosci Lett 1996; 209(1):41-4.
41. Driver HS, Flanigan MJ, Bentley AJ et al. The influence of ipsapirone, a 5-HTlA agonist, on sleep patterns of healthy subjects. Psychopharmacology (Berl) 1995; 117(2): 186-92.
42. Moore P, Seifritz E, Schlosser A et al. Rapid tryptophan depletion plus a serotonin lA agonist: Competing effects on sleep in healthy men. Neuropsychopharmacology 2001; 25(5 Suppl):S40-4.
43. Ansseau M, Pitchot W, Gonalez-Moreno A. Flesinoxan, a 5HTIA agonist, in major depression: Clinical efficacy and effects on REM latency and body temperature (open study). European Neuropsychopharmacology 1992; 2:313.
44. Wilson SJ, Bailey JE, Rich AS et al. Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram. Eur Neuropsychopharmacol 2004;14(5):367-72.
45. Bell C, Wilson S, Rich A et al. Effeas on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers. Psychopharmacology Berl 2003; 166(2): 102-10.
46. Hartmann E. Sleep Research 1979; 8:98.
47. Hendrickse WA, Rofiwarg HP, Granneman BD et al. The effects of fluoxetine on the polysomnogram of depressed outpatients: A pilot study. Neuropsychopharmacology 1994; 10:85-91.
48. Jindal RD, Friedman ES, Berman SR et al. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol 2003; 23(6):540-8.
49. Kupfer DJ, Perel JM, Pollock BG et al. Fluvoxamine versus desipramine: comparative polysomnographic effects. Biological Psychiatry 1991; 29:33-40.
50. Nicholson AN, Pascoe PA Studies on the modulation of the sleep-wakeftilness continuum in man by fluoxetine, a 5HT uptake inhibitor. Neuropharmacology 1988; 27:597-602.
51. Oswald I, Adam K. Effects of paroxetine on human sleep. Br J Clin Pharmacol 1986; 22(1):97-9.
52. Roschke J, Kogel P, Schlosser R et al. Analysis of sleep EEC microstructure in subchronic paroxetine treatment of healthy subjeas Psychopharmacology (Berl) 1997; 132(1):44-9.
53. Saletu B, Frey R, Krupka M et al. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 1991; 14(5):439-47.
54. Schlosser R, Roschke J, Rossbach W et al. Conventional and spectral power analysis of all-night sleep EEC after subchronic treatment with paroxetine in healthy male volunteers. Eur Neuropsychopharmacol 1998; 8(4):273-8.
55. Sharpley AL, Williamson DJ, Attenburrow ME et al. The effects of paroxetine and nefazodone on sleep: A placebo controlled trial. Psychopharmacology (Berl) 1996; 126(1):50-4.
56. Staner L, Kerkhofs M, Detroux D et al. Acute, subchronic and withdrawal sleep EEC changes during treatment with paroxetine and amitriptyline: A double-blind randomized trial in major depression. Sleep 1995; 18(6):470-7.
57. Trivedi MH, Rush AJ, Armitage R et al. Effeas of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology 1999; 20(5):447-59.
58. Winokur A, DeMartinis NA 3rd, McNally DP et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Clin Psychiatry 2003; 64(10): 1224-9.